title: Development of Passive Immunotherapies for Synucleinopathies.
abstract: Immunotherapy using antibodies targeting alpha-synuclein has proven to be an effective strategy for ameliorating pathological and behavioral deficits induced by excess pathogenic alpha-synuclein in various animal and/or cellular models. However, the process of selecting the anti-alpha-synuclein antibody with the best potential to treat synucleinopathies in humans is not trivial. Critical to this process is a better understanding of the pathological processes involved in the synucleinopathies and how antibodies are able to influence these. We will give an overview of the first proof-of-concept studies in rodent disease models and discuss challenges associated with developing antibodies against alpha-synuclein resulting from the distribution and structural characteristics of the protein. We will also provide a status on the passive immunization approaches targeting alpha-synuclein that have entered, or are expected to enter, clinical evaluation.
authors.affiliation: Division of Neurodegeneration and Biologics, H. Lundbeck A/S, Valby, Denmark.
authors.forename: Ann-Louise
authors.initials: AL
authors.lastname: Bergström
authors.affiliation: Division of Neurodegeneration and Biologics, H. Lundbeck A/S, Valby, Denmark.
authors.forename: Pekka
authors.initials: P
authors.lastname: Kallunki
authors.affiliation: Division of Neurodegeneration and Biologics, H. Lundbeck A/S, Valby, Denmark.
authors.forename: Karina
authors.initials: K
authors.lastname: Fog
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D007116:Immunization, Passive / Q000379:methods*; D020961:Lewy Body Disease / Q000628:therapy*; D019578:Multiple System Atrophy / Q000628:therapy*; D010300:Parkinson Disease / Q000628:therapy*; D051844:alpha-Synuclein / Q000737:chemistry* / Q000276:immunology*
chemical_list: D051844:alpha-Synuclein
keywords: Alpha-synuclein; Parkinson's disease, synucleinopathies; mechanism of action; passive immunization